(Q38017369)

27 August 2017

title

The protein C pathway in cancer metastasis (English)

1 reference

27 August 2017

1 reference

C Arnold Spek

1

1 reference

27 August 2017

Valder R Arruda

series ordinal

2

1 reference

27 August 2017

publication date

1 April 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

129 Suppl 1

1 reference

27 August 2017

page(s)

S80-4

1 reference

Cancer and thrombosis: from molecular mechanisms to clinical presentations

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Trousseau's syndrome: multiple definitions and multiple mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Malignancies, prothrombotic mutations, and the risk of venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Effect of anticoagulant drugs in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Molecular basis for the relationship between thrombosis and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

The effect of low molecular weight heparin on survival in patients with advanced malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Heparin and survival in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Antimetastatic effect of tinzaparin, a low-molecular-weight heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

The Protein C Pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Deficiency of protein C in congenital thrombotic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

The role of thrombomodulin in malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

A subcloned human esophageal squamous cell carcinoma cell line with low thrombomodulin expression showed increased invasiveness compared with a high thrombomodulin-expressing clone--thrombomodulin as a possible candidate for an adhesion molecule of

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Role of activated protein C and its receptor in inhibition of tumor metastasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Treatment of endothelium with the chemotherapy agent vincristine affects activated protein C generation to a greater degree in newborn plasma than in adult plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Chemotherapy for breast cancer decreases plasma protein C and protein S.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

PAR1 signaling: more good than harm?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Activated protein C decreases tumor necrosis factor related apoptosis-inducing ligand by an EPCR- independent mechanism involving Egr-1/Erk-1/2 activation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Protective signaling pathways of activated protein C in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Endogenous activated protein C is essential for immune-mediated cancer cell elimination from the circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Activated protein C in sepsis: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Long-term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

A low molecular weight heparin inhibits experimental metastasis in mice independently of the endothelial glycocalyx

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Sphingosine-1-phosphate receptor subtype-specific positive and negative regulation of Rac and haematogenous metastasis of melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Meningococcal septicaemia: treatment with protein C concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Protein C concentrate to restore physiological values in adult septic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Human protein C zymogen concentrate in patients with severe sepsis and multiple organ failure after adult cardiac surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

PROTEIN C CONCENTRATE AS ADJUVANT TREATMENT IN NEONATES WITH SEPSIS-INDUCED COAGULOPATHY

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Administration of human protein C improves survival in an experimental model of sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Protein C concentrate controls leukocyte recruitment during inflammation and improves survival during endotoxemia after efficient in vivo activation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

Treatment of the critically ill patient with protein C: is it worth the cost?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2812%2970022-1

7 January 2021

10.1016/S0049-3848(12)70022-1

Identifiers

DOI

1 reference

27 August 2017

1 reference